Crossref
Real‐world sequencing of second‐line systemic therapy and outcomes in metastatic pancreatic ductal adenocarcinoma: an analysis of the PURPLE registry
Asia-Pacific Journal of Clinical Oncology · 2026-11 · 22 (S6) · 28-28
DOI: 10.1111/ajco.70243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 19.11.2026.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Real‐world sequencing of second‐line systemic therapy and outcomes in metastatic pancreatic ductal adenocarcinoma: an analysis of the PURPLE registry. Asia-Pacific Journal of Clinical Oncology, 22(S6), 28-28. https://doi.org/10.1111/ajco.70243
Vancouver
Real‐world sequencing of second‐line systemic therapy and outcomes in metastatic pancreatic ductal adenocarcinoma: an analysis of the PURPLE registry. Asia-Pacific Journal of Clinical Oncology. 2026;22(S6):28-28. doi:10.1111/ajco.70243
BibTeX
@article{euvimed2026,
title = {Real‐world sequencing of second‐line systemic therapy and outcomes in metastatic pancreatic ductal adenocarcinoma: an analysis of the PURPLE registry},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {S6},
pages = {28--28},
doi = {10.1111/ajco.70243}
}
EUVIMED